BACKGROUND: The ABC (age, biomarker, clinical history)-stroke and ABC-bleeding risk scores incorporate clinical variables and cardiovascular biomarkers to estimate risk of stroke or systemic embolic events and bleeding, respectively, in patients with atrial fibrillation. These scores have been proposed for routine clinical use, but their performance in external cohorts remains uncertain.
S
troke and systemic embolism are morbid and often fatal complications of atrial fibrillation (AF). 1 Oral anticoagulation in patients with AF significantly reduces the risk of stroke or systemic embolic events (S/SEE) but increases the risk of major bleeding. Current guidelines recommend systematically evaluating the absolute risks of S/SEE and bleeding estimated with clinical risk scores such as the CHA 2 DS 2 -VASc and HAS-BLED scores, respectively, when making decisions about oral anticoagulation. [2] [3] [4] Despite the availability of these scores and guidelines for treatment, a surprisingly high proportion of patients with AF go untreated, in particular because of concern about the risk of bleeding. [5] [6] [7] In research dating back for more than a decade, multiple studies have suggested that circulating biomarkers of cardiovascular disease may improve the prediction of S/SEE and bleeding in patients with AF compared with established clinical risk scores. [8] [9] [10] [11] [12] [13] In an analysis of a cohort from the ENGAGE AF-TIMI 48 trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48), we previously demonstrated that incorporating a conventional assay for cardiac troponin I, NT-proBNP (Nterminal B-type natriuretic peptide), and D-dimer into a multimarker risk score for S/SEE and death significantly enhanced prognostic accuracy compared with or when added to the CHA 2 DS 2 -VASc score. 14 The novel ABC (age, biomarker, clinical history)-stroke and ABC-bleeding risk scores also incorporate biomarkers, along with clinical variables, to estimate risk of S/SEE and bleeding, respectively. 15, 16 The components of the ABC-stroke score include age, NT-proBNP, high-sensitivity cardiac troponin T (hsTnT), and prior stroke/transient ischemic attack (TIA), and the components of the ABC-bleeding score include age, growth differentiation factor-15 (GDF-15), hsTnT, hemoglobin, and history of bleeding. 15, 16 Although the ABC-stroke and ABC-bleeding scores outperformed the CHA 2 DS 2 -VASc and HAS-BLED scores, respectively, in their predictive accuracy in the derivation cohorts, 15, 16 their performance in external cohorts remains uncertain. 17, 18 Given the current equipoise about the clinical use of the biomarker-based ABC scores, we designed a nested biomarker study to independently evaluate the prognostic performance and to identify novel applications of these risk scores in patients with AF in a well-characterized cohort from a large multinational clinical trial. 19 
METHODS

Study Population and Design
The ENGAGE AF-TIMI 48 trial was a multinational randomized double-blind trial of the oral factor Xa inhibitor edoxaban versus warfarin for the prevention of stroke and systemic embolism in 21 105 patients with AF and CHADS 2 score ≥2. 19 Patients randomized to edoxaban received either a higher-dose edoxaban regimen (HDER) with edoxaban 60/30 mg daily or a lower-dose edoxaban regimen (LDER) with edoxaban 30/15 mg daily. Patients randomized to warfarin were dosed to reach a target international normalized ratio of 2.0 to 3.0. The median follow-up was 2.8 years. Participation in a prospective nested biomarker substudy was offered to all enrolled patients at sites that elected to participate in the biomarker substudy until ≈9000 patients were recruited. For this analysis, collected samples were available for 8705 patients from the time of trial enrollment (baseline) and for 6806 patients at 12 months after trial enrollment. All patients provided written informed consent. The protocol was approved by ethics committees at each center. We encourage parties interested in collaboration and data sharing to contact the corresponding author directly for further discussions.
Biomarkers
Baseline blood samples were collected on the day of randomization, which was the same day that the first dose of study drug was administered. Samples were collected in EDTA
Clinical Perspective
What Is New?
• In this independent external validation, the ABC (age, biomarker, clinical history)-stroke and ABCbleeding risk scores performed well for stratifying the risk of stroke or systemic embolic events and major bleeding in a well-characterized anticoagulated cohort from a large multinational trial.
• Compared with the CHA 2 DS 2 -VASc score, the ABCstroke score provides both correct upward and downward reclassification of stroke or systemic embolic event risk. Compared with the HAS-BLED score, the ABC-bleeding score results in predominantly correct downward reclassification of bleeding risk.
• Increases in high-sensitivity troponin T, NT-proBNP (N-terminal B-type natriuretic peptide), and growth differentiation factor-15 over 12 months were independently associated with increased risk of stroke or systemic embolic events and major bleeding.
What Are the Clinical Implications?
• Our analysis suggests that incorporating the biomarker-based ABC-stroke and ABC-bleeding risk scores into clinical practice may improve the riskbenefit assessment of patients with AF considering anticoagulation.
• Application of these scores may help to identify patients who are most likely to derive a clinical benefit from treatment with non-vitamin K antagonist oral anticoagulants compared with warfarin. 
Clinical End Points
The primary efficacy end point was the time to first adjudicated stroke (ischemic or hemorrhagic) or systemic embolic event.
The primary safety end point was major bleeding, which was adapted from the International Society on Thrombosis and Hemostasis definition. This end point included fatal bleeding; bleeding in a critical area or organ such as intracranial, intraspinal, intraocular, retroperitoneal, intra-articular, pericardial, or intramuscular with compartment syndrome; or bleeding causing a fall in hemoglobin level of ≥2 g/dL (adjusted for transfusion) or leading to transfusion of ≥2 U whole blood or red cells. The primary net clinical outcome (NCO) was the composite of stroke, systemic embolic event, major bleeding, or death resulting from any cause. An independent clinical events committee, blinded to study assignment, adjudicated all outcomes.
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Statistical Methods
Baseline characteristics stratified by prespecified biomarker categories for hsTnT, NT-proBNP, and GDF-15 were summarized. Univariate associations between individual biomarkers and the clinical outcomes of S/SEE and major bleeding were assessed with the use of a Cox proportional hazard model with the biomarker as the independent variable. These analyses were performed with the biomarker modeled as both a continuous and a categorical variable using a priori thresholds. On the basis of the distribution of biomarker values, continuous data were log transformed. Event rates were estimated and displayed with annualized event rates. Adjusted estimates of the association between individual biomarkers and S/SEE were calculated from a Cox proportional hazard model with the biomarker as an independent variable, along with estimated glomerular filtration rate (eGFR) and each of the elements of the CHA 2 DS 2 -VASc score (age, sex, history of heart failure, history of hypertension, history of known atherosclerosis, diabetes mellitus, and history of stroke or TIA). Similarly, adjusted estimates of the association between individual biomarkers and major bleeding were calculated from a Cox proportional hazard model with the biomarker as an independent variable, along with eGFR and each of the elements of the HAS-BLED score (age, history of hypertension, history of abnormal renal or liver function, history of stroke or TIA, history of major bleeding, medication use predisposing to bleeding, and alcohol use). International normalized ratio lability (a component of the HAS-BLED score) was not included because there were no available international normalized ratio data before randomization and 40% of patients enrolled in the trial were naïve to vitamin K antagonists.
The univariate and multivariable analyses were repeated with the use of the absolute biomarker values at 12 months, as well as the absolute change (ie, delta) in biomarker values from randomization to 12 months using a priori thresholds. For these analyses, a landmark analysis of S/SEE and bleeding outcomes starting at 12 months was performed.
Multivariable analyses were performed assessing the ABCstroke and ABC-bleeding risk score variables in a Cox proportional hazard model with eGFR and each of the risk score components (ABC-stroke: age, NT-proBNP, hsTnT, and prior stroke/TIA; ABC-bleeding: age, GDF-15, hsTnT, hemoglobin, and history of bleeding). The discriminatory performance was assessed with Harrell's c index [21] [22] [23] for the CHA 2 DS 2 -VASc and HAS-BLED scores, for each biomarker alone, for the ABCstroke and ABC-bleeding risk scores using both coefficients for the regression models derived in ENGAGE AF-TIMI 48 and those from the original derivation cohorts, and for comprehensive clinical and biomarker models for S/SEE and major bleeding tested during the previous derivation of the scores. 12, 13 The predictive performance (ie, c indexes) of these correlated models was compared by use of the approach described by Kang et al. 24 To estimate the relative prognostic information provided by the ABC-stroke and ABC-bleeding risk models compared with the comprehensive S/SEE and bleeding models, respectively, we approximated the comprehensive models using ordinary least-squares models in which the estimated linear predictors from the full Cox model were the outcome variables and the components of the ABC-stroke and ABCbleeding risk scores were the covariates. Reclassification was assessed by calculating the categorical net reclassification improvement (NRI) at 1 year with the ABC-stroke versus CHA 2 DS 2 -VASc scores and ABC-bleeding versus HAS-BLED scores using prespecified categorical subgroups defined by 1-year predicted risks of S/SEE and major bleeding (<1%, 1%-2%, >2%). These thresholds were selected on the basis of previous evaluations of the ABC risk score performance in AF. In addition, we performed a sensitivity analysis for the NRI of the ABC-stroke versus CHA 2 DS 2 -VASc scores, using 0.75% as a single threshold for 1-year risk of S/SEE. Annualized S/SEE event rates were described according to (1) categorical subgroups defined by 1-year S/SEE risk predicted by the ABC-stroke score (<1%, 1%-2%, >2%) and categorical subgroups defined by the CHA 2 DS 2 -VASc score (≤3, 4, ≥5) and (2) categorical subgroups defined by 1-year S/SEE risk predicted by the ABC-stroke score (<1%, 1%-2%, >2%) and categorical subgroups defined by a previously reported TIMI-AF clinical risk score (low, intermediate, high). 25 Similarly, annualized major bleeding event rates were described according to (1) categorical subgroups defined by 1-year major bleeding risk predicted by the ABC-bleeding score (<1%, 1%-2%, >2%) and categorical subgroups defined by the HAS-BLED score (0-1, 2, 3, ≥4) and (2) categorical subgroups defined by 1-year major bleeding risk predicted by the ABC-bleeding score (<1%, 1%-2%, >2%) and categorical subgroups defined by the TIMI-AF clinical risk score (low, intermediate, high). 25 Calibration of the ABC-stroke and ABC-bleeding risk scores was assessed by categorizing patients into strata using ORIGINAL RESEARCH ARTICLE the estimated 1-year S/SEE and bleeding risks from the ABCstroke and ABC-bleeding scores and comparing the predicted risk in each group with the observed rate, as well as by calculating the Nam-D'Agostino statistic. 26 To test for interaction between the treatment effect of edoxaban versus warfarin and baseline ABC-stroke and ABC-bleeding risk scores, Cox regression was performed with the main effects and interaction terms. The proportional hazards assumption was confirmed with statistical tests and visual inspection based on the scaled Schoenfeld residuals. Pairwise comparisons between each of the 2 edoxaban exposure groups (HDER and LDER) and warfarin were performed.
Data were analyzed with R version 3.5.0. Categorical variables are shown as counts and percentages based on the number of patients with available data for that parameter; continuous variables are shown as medians (25th-75th percentiles). Differences in the baseline characteristics between biomarker strata were evaluated with the Pearson χ 2 test for categorical variables and Kruskal-Wallis test for continuous variables.
AF indicates atrial fibrillation; ASA, acetylsalicylic acid (aspirin); BMI, body mass index; CAD, coronary artery disease; CrCl, creatinine clearance; dz, disease; GDF-15, growth differentiation factor-15; hsTnT, high-sensitivity troponin T; Hx, history; ICH, intracranial hemorrhage; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal B-type natriuretic peptide; OAC, oral anticoagulant; PAD, peripheral artery disease; TIA, transient ischemic attack; and T2DM, type 2 diabetes mellitus.
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RESULTS
Baseline Characteristics
The median baseline hsTnT, NT-proBNP, and GDF-15 values in the 8705 patients in the nested biomarker analysis were 13.7 ng/L (25th-75th percentiles, 9.6-20.4 ng/L), 811 pg/mL (386-1436 pg/mL), and 1661 pg/mL (1179-2427 pg/mL), respectively. Baseline characteristics stratified by prespecified biomarker categories for hsTnT (<7, 7-<14, ≥14 ng/mL), NT-proBNP (<450, 450-<900, ≥900 pg/mL), and GDF-15 (<1200, 1200-<1800, ≥1800 pg/mL) are shown in Table 1 (baseline characteristics for the full cohort are shown in Table I in the online-only Data Supplement). Patients in the highest categories of hsTnT, NT-proBNP, and GDF-15 were older, had worse renal function, and had a higher prevalence of coronary artery disease at the time of trial enrollment (all P<0.001).
Individual Biomarkers at Baseline and 1 Year
After adjustment for the effects of eGFR and each of the elements of the CHA 2 DS 2 -VASc score (age, sex, history of heart failure, history of hypertension, history of known atherosclerosis, diabetes mellitus, and history of stroke or TIA), in a comparison of the highest and lowest biomarker categories for each biomarker, hsTnT, NT-proBNP, and GDF-15 were each independently associated with a >2-fold higher rate of S/SEE (P<0.001; Figure 1 ). After adjustment for the effects of eGFR and each of the elements of the HAS-BLED score (age, history of hypertension, history of abnormal renal or liver function, history of stroke or TIA, history of major bleeding, medication use predisposing to bleeding, and alcohol use), in a comparison of the highest and lowest biomarker categories for each biomarker, hsTnT and GDF-15 were each independently associated with a >2-fold higher rate of bleeding (P<0.001), whereas NT-proBNP was not ( Figure 1 ). When analyzed as a continuous variable, each biomarker was independently associated with both outcomes (Table II in the online-only Data Supplement). In multivariable models including all 3 biomarkers, GDF-15 was no longer independently associated with S/SEE and NT-proBNP was no longer independently associated with major bleeding. The median hsTnT, NT-proBNP, and GDF-15 values at 12 months after trial enrollment among the 6806 patients with available data from the nested biomarker cohort were 13.8 ng/L (25th-75th percentiles, 9.6-20.7 ng/L), 773 pg/mL (367-1362 pg/mL), and 1711 pg/mL (1199-2563 pg/mL), respectively. From a landmark of 12 months after trial enrollment, hsTnT, NT-proBNP, and GDF-15 remained independently associated with higher rates of subsequent S/SEE, and GDF-15 remained independently associated with higher rates of major bleeding, but hsTnT did not (Table III in Among patients with serial biomarker measurements, a >6-ng/mL increase in the value of hsTnT, a >800-pg/mL increase in the value of NT-proBNP, and a >1200-pg/mL increase in the value of GDF-15 between randomization and 12 months were each independently associated with higher rates of S/SEE (Table III in the online-only Data Supplement). Similarly, a >6-ng/ mL increase in the value of hsTnT and a >1200-pg/mL increase in the value of GDF-15 between randomization and 12 months were each independently associated with higher rates of major bleeding (Table III in The components of the CHA 2 DS 2 -VASc score include age, sex, history of heart failure, history of hypertension, history of known atherosclerosis, diabetes mellitus, and history of stroke or transient ischemic attack (TIA). The components of the HAS-BLED include age, history of hypertension, history abnormal renal or liver function, history of stroke or TIA, history of major bleeding, medication use predisposing to bleeding, and alcohol use (international normalized ratio lability not included). The components of the ABC-stroke score include age, NT-proBNP (N-terminal B-type natriuretic peptide), high-sensitivity troponin T (hsTnT), and prior stroke/TIA. The components of the ABC-bleeding score include age, prior bleeding, hemoglobin, hsTnT, and GDF-15.
*The comprehensive models include the all of the clinical and biomarker variables that were included in the comprehensive models from the derivation cohort 15, 16 (shown Figure 2) . †Notably, GDF-15 and cystatin C were included in the full bleeding model but not in the comprehensive S/SEE model in the derivation cohort. 15, 16 In addition, D-dimer, which had been included in a previous multimarker risk score for S/SEE and death derived in ENGAGE AF-TIMI 48, 14 was not included in the comprehensive S/SEE model in the derivation cohort. 15 Therefore, the C index for an additional model that included the full model for S/SEE in the derivation cohort plus GDF-15, cystatin C, and D-dimer is shown. 
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ABC-Stroke and ABC-Bleeding Scores
Each clinical variable and biomarker modeled in the ABC-stroke and ABC-bleeding derivation cohorts 15, 16 was reassessed in our cohort ( Figure 2 ). Consistent with the findings in the original derivation cohort, the strongest predictors of stroke and systemic embolic events were NT-proBNP, age, history of stroke/TIA, and hsTnT, mirroring the components of the ABC-stroke score ( Figure 2A ). The ABC-stroke score variables accounted for 94.3% of the prognostic information provided by the clinical and biomarker variables included in a comprehensive model in the derivation cohort. Moreover, including additional cardiovascular biomarkers (GDF-15, cystatin C, and D-dimer) in the model for S/ SEE did not improve the prognostic performance of the ABC-stroke risk score ( Table 2 ). The strongest predictors of major bleeding were age, history of bleeding, hemoglobin, and GDF-15. In our cohort, hsTnT was a statistically significant but less strong predictor of bleeding, with an effect size similar to alcohol use, current smoking, and history of peripheral artery disease ( Figure 2B ). The ABC-bleeding score variables accounted for 90.3% of the prognostic information provided by the clinical and biomarker variables included in a comprehensive model in the derivation cohort.
The ABC-stroke risk score applied using model coefficients derived in our cohort yielded a c index of 0.67 (95% CI, 0.65-0.70) for prediction of S/SEE compared with a c index of 0.59 (95% CI, 0.57-0.62) for the CHA 2 DS 2 -VASc score (P<0.001). The ABC-stroke risk score discrimination applied using the coefficients from the original derivation model was highly consistent, with a c index of 0.66 (95% CI, 0.63-0.68) for prediction of S/SEE. The overall NRI at 1 year was 25.2% (95% CI, 13.1-46.1), with similar proportions of correct upward and downward reclassification (Table 3) . In a sensitivity analysis with 0.75% used as a single threshold for 1-year risk of S/SEE, the NRI at 1 year was 11.7% (95% CI, 7.0-18.6).
The ABC-bleeding risk score in our cohort yielded a c index of 0.69 (95% CI, 0.66-0.71) for the prediction of major bleeding compared with a c index of 0.62 (95% CI, 0.60-0.64) for the HAS-BLED score (P<0.001). Similarly, the ABC-bleeding risk score applied with model coefficients from the original derivation cohort yielded a c index of 0.67 (95% CI, 0.65-0.70) for the prediction of major bleeding. The overall NRI at 1 year was 13.8% (95% CI, 8.0-22.8) with predominantly correct downward reclassification (Table 3) .
Moreover, the ABC-stroke and ABC-bleeding risk scores accurately stratified patients regardless of CHA 2 DS 2 -VASc (P trend <0.001) and HAS-BLED (P trend <0.001) risk score categories, respectively (Figure 3) ; this pattern was consistent across all treatment groups ( Figure I in the online-only Data Supplement). In addition, the ABC-stroke and ABC-bleeding risk scores further stratified S/SEE and bleeding risk within categories of the previously reported TIMI-AF clinical risk score, 25 although it should be noted that the TIMI-AF risk score was designed to predict NCOs rather than S/ SEE or bleeding alone ( Figure II in the online-only Data Supplement).
The ABC-stroke and ABC-bleeding risk scores were well calibrated, with observed cumulative incidence rates of S/SEE and major bleeding within each stratum of risk matching the 1-year risks predicted by the ABCstroke and ABC-bleeding scores using both the coefficients for the regression models from ENGAGE AF-TIMI 48 ( Figure 4 
Treatment Interactions
In comparisons of each edoxaban treatment group and warfarin, there was no heterogeneity in the performance of either the ABC-stroke score (HDER versus warfarin, P for interaction=0.99; LDER versus warfarin, P for interaction=0.94) or the ABC-bleeding score (HDER versus warfarin, P=0.84; LDER versus warfarin, P=0.95; Table IV in the online-only Data Supplement).
For patients with ABC-bleeding scores predicting 1-year major bleeding risks of <1% (low), 1% to 2% (intermediate), and >2% (high), observed annualized major bleeding rates were 0.37%, 1.54%, and 3.92% in the HDER arm and 0.43%, 1.01%, and 2.66% in the LDER arm, respectively. Compared with patients in the warfarin arm, the absolute reductions in annualized major bleeding rates were 0.35%, 0.40%, and 0.72% for patients in the HDER arm with low, intermediate, and high risk of major bleeding and 0.29%, 0.93%, and 1.98% for patients in the LDER arm.
For patients with ABC-stroke and ABC-bleeding scores predicting 1-year S/SEE and major bleeding risks of <1%, the rates of the NCO between patients treated with edoxaban versus warfarin were very similar (HDER, 1.48%/y; LDER, 1.43%/y; warfarin, 1.38%/y; Table 4 ). However, for patients with ABC-bleeding scores predicting 1-year major bleeding risks of >2%, observed rates of the NCO were more favorable in both the HDER and LDER arms compared with the warfarin arm regardless of stroke risk. Among patients with elevated ABC-bleeding scores (>2%), those with elevated ABC-stroke scores (>2%) derived the greatest benefit from HDER (NCO: HDER, 8.31%/y; LDER, 9.22%/y; warfarin, 10.91%/y), and those with low ABC-stroke scores (<1%) derived the greatest benefit from LDER (NCO: HDER, 3.57%/y; LDER, 2.44%/y; warfarin, 4.25%/y; Table 4 ).
DISCUSSION
In this nested prospective biomarker substudy of the ENGAGE AF-TIMI 48 trial, we demonstrated that hsTnT, NT-proBNP, and GDF-15-3 circulating biomarkers of underlying cardiovascular disease-were independently associated with risk of S/SEE and that hsTnT and GDF-15 were independently associated with risk of major bleeding in patients with AF. Moreover, we independently confirmed the prognostic performance of the ABC-stroke and ABC-bleeding risk scores for the prediction of S/SEE and major bleeding, respectively, in a well-characterized anticoagulated cohort from a large multinational clinical trial. Compared with previous work, we found that correct upward and downward reclassification of stroke risk and predominantly correct downward reclassification of bleeding risk may identify patients whose risk-benefit profile more clearly favors treatment, ameliorating the current treatment gap that exists in patients with AF. Although a high bleeding risk in itself should not automatically result in the decision not to anticoagulate because stroke risk tracks along with bleeding risk, using the ABC-bleeding score, which provides a more precise estimate of bleeding risk, may empower physicians and patients to make betterinformed treatment decisions. In addition, we showed that simultaneous application of the ABC-stroke and ABC-bleeding risk scores can identify patients who are ORIGINAL RESEARCH ARTICLE most likely to derive a benefit from treatment with nonvitamin K antagonist oral anticoagulants compared with warfarin. Lastly, extending beyond prior work, we demonstrated the stable prognostic contribution of the biomarkers after 1 year of clinical follow-up while anticoagulation is continued and found that increases in these biomarkers over a 12-month period were independently associated with increased risk of S/SEE and major bleeding. These data support the concept that biomarker-based risk scores improve prediction of S/SEE and major bleeding in patients with AF compared with established clinical risk scores, may be useful for therapeutic decision making, and warrant consideration in management guidelines.
Potential for Application of the ABC Scores in Clinical Practice
Although risk scores based on clinical variables only, including the CHA 2 DS 2 -VASc and HAS-BLED scores, are widely used by clinicians, multiple studies have demonstrated modest prognostic performance. [14] [15] [16] In addition, several prior studies have established that incorporating multiple as opposed to single biomarkers of cardiovascular disease into risk prediction tools enhances their discriminatory performance, perhaps by capturing orthogonal information about distinct pathways implicated in thrombosis and vascular integrity. For example, in a previous analysis from the ENGAGE AF-TIMI 48 trial, incorporating a conventional assay for cardiac troponin I, NT-proBNP, and D-dimer into a multimarker risk score for S/SEE and death significantly enhanced the prognostic accuracy of the CHA 2 DS 2 -VASc score.
14 Among the risk prediction tools that have Observed annualized event rates are shown as percent of patients at-risk. A, The ABC-stroke risk score accurately stratified patients regardless of CHA 2 DS 2 -VASc risk score categories (P trend <0.001). B, The ABC-bleeding risk score accurately stratified patients regardless of HAS-BLED risk score categories (P trend <0.001).
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been developed for patients with AF, the ABC-stroke and ABC-bleeding risk scores have been proposed for routine clinical use 27 ; however, their performance in validation cohorts has been variable. Specifically, although the ABC-stroke and ABC-bleeding risk scores outperformed the CHA 2 DS 2 -VASc and HAS-BLED scores in the original validation cohorts derived from the STABILITY trial (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy; n=1400) and RE-LY trial (Randomized Evaluation of Long-Term Anticoagulation Therapy; n=8468), respectively, 15, 16 the prognostic performance of a modified ABC-bleeding score was not significantly better than that of the HAS-BLED risk score in a smaller nonclinical trial cohort from the Murcia Atrial Fibrillation Project (n=1120). 17, 18 Although the differential performance of the modified ABC-bleeding score in this nonclinical trial cohort may have been related to incomplete biomarker data (GDF-15 was not included in the risk score) or inadequate power, it has also been suggested that it may have been related to the higher prevalence of non-AF comorbidities in this population. 17, 18 Because the circulating biomarkers in the ABC scores are elevated in multiple different disease states, 28, 29 it is possible that patients with more non-AF comorbidities have serum biomarker levels that do not necessarily reflect their thrombotic or bleeding risk. Although this analysis was performed in a clinical trial population, ENGAGE AF-TIMI 48 enrolled a higher-risk population with a greater burden of comorbid diseases compared with the clinical trial populations in which the ABC scores were derived and initially validated. [30] [31] [32] The results of this analysis therefore represent an important step forward in establishing a robust evidence base for potential clinical use of the ABC scores by providing additional realistic estimates of their discriminatory and reclassification performance.
Although there was some variability in the relative effect sizes of the individual components of the ABCbleeding score in our cohort compared with the original derivation cohort, the overall discriminatory performance of both the ABC-stroke and ABC-bleeding scores was similar between cohorts. Moreover, when evaluated collectively, the ABC-stroke and ABC-bleeding score variables accounted for 94.3% and 90.3% of the prognostic information provided by comprehensive models for S/SEE and major bleeding, 15, 16 respectively. These data indicate that traditional clinical risk factors other than age and history of S/SEE and bleeding add very little additional discriminatory information beyond what is provided by the cardiovascular biomarkers included in the ABC-stroke and ABC-bleeding scores.
The implications of these findings are several-fold. First, given the reproducible performance of the ABCstroke and ABC-bleeding risk scores for predicting S/ SEE and major bleeding in patients with AF on anticoagulation, clinicians should consider using these biomarker-based risk scores rather than traditional clinical risk scores when making decisions about oral anticoagulation. For example, simultaneous application of these instruments may help to identify patients at increased risk for S/SEE and relatively lower risk for major bleeding in whom anticoagulation would be favored. However, no data are available yet on the performance of the ABC risk scores in a population of patients with AF not receiving anticoagulation, for whom application of the ABC scores would be particularly useful. Because all patients in the ENGAGE AF-TIMI 48 trial received anticoagulation, the results reported in this analysis should not be interpreted as identifying patients at sufficiently low risk of S/SEE to defer anticoagulation. Additional validation of the ABC scores in a lower-risk population and in patients not on anticoagulation would be neces- A, The observed cumulative incidence of S/SEE over the first 3 years after trial enrollment was stratified by the 1-year risk of S/SEE predicted by the ABC-stroke score (<1%, 1%-2%, >2%). The observed annualized event rates (shown for each risk group) were significantly different across strata (P<0.001). B, The observed cumulative incidence of major bleeding over the first 3 years after trial enrollment was stratified by the 1-year risk of major bleeding predicted by the ABC-bleeding score (<1%, 1%-2%, >2%). The observed annualized event rates (shown for each risk group) were significantly different across strata (P<0.001).
Circulation. ORIGINAL RESEARCH ARTICLE sary to establish the evidence base to support such application of the ABC-stroke score. Second, given the relative stability of the biomarker values over a 12-month period and the consistent risk prediction between the primary analysis of baseline biomarker values and the landmark analysis using biomarker values at 12 months after randomization, the ABC scores appear to provide steady and robust estimates of risk. Finally, the ABC risk scores seem to perform equally well in patients treated with warfarin and those treated with edoxaban, helping to identify patients who derive the greatest absolute benefit from treatment with edoxaban compared with warfarin. Specifically, among patients with ABCbleeding scores predicting 1-year major bleeding risk of >2%, those with high ABC-stroke scores (ie, predicting 1-year S/SEE risk >2%) derive the greatest net clinical benefit from HDER, and those with low ABC-stroke scores (<1%) derive the greatest net clinical benefit from LDER. This finding illustrates the potential of the ABC-stroke score to identify low-risk individuals who are candidates for less intensive anticoagulation. By enhancing the precision of estimated stroke and bleeding risks and directly informing treatment decisions, the ABC scores support the movement toward precision medicine. Nevertheless, the decision to use any biomarker-based tool for risk stratification might be individualized and weighed against the ease of using traditional clinical risk scores, which do not require laboratory testing. For example, it may not be necessary to perform additional testing for risk stratification when the risk-benefit calculus clearly favors oral anticoagulation even though application of a biomarker-based score may provide a more precise estimate of risk.
Limitations
Several limitations of this analysis should be acknowledged. All patients in the ENGAGE AF-TIMI 48 trial received anticoagulation, whereas the CHA 2 DS 2 -VASc score was developed in patients who were not receiving anticoagulants. Despite this difference, prior studies of the CHA 2 DS 2 -VASc score have shown similar discriminatory performance in patients receiving 8, 9 and not receiving anticoagulation. 33, 34 Moreover, in our analysis, the ABC-stroke score outperformed the CHA 2 DS 2 -VASc score among patients treated with LDER (a less effective regimen for S/SEE prevention than HDER or warfarin). These data suggest that the ABC-stroke score is robust across varying levels of anticoagulation exposure. Still, it should be clear that our analysis provides a better estimate of major bleeding risk on anticoagulation than of S/SEE risk off anticoagulation. Because this is the primary clinical question of interest to clinicians, it would be ideal to assess the performance of the ABC-stroke score in a population of patients with AF not receiving anticoagulation as well. Given the widespread use of anticoagulation in all but the lowest-risk patients in the modern era, it may not be feasible or ethical to conduct such an analysis in this population; however, doing so in a low-risk population not on anticoagulation in future validation studies would be useful for addressing this knowledge gap.
In addition, this validation was performed in a clinical trial cohort, which may affect the generalizability of the findings. Although ENGAGE AF-TIMI 48 enrolled a higher-risk population with a greater burden of comorbid diseases compared with the clinical trial populations in which the ABC scores were derived, 30-32 addi- 
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tional well-powered studies in nonclinical trial cohorts would be helpful to confirm whether the ABC risk scores will improve discrimination of S/SEE and bleeding outcomes when applied to unselected populations in clinical practice.
Other limitations of our analysis deserve mention. First, because the ENGAGE AF-TIMI 48 trial excluded patients at low risk for S/SEE (ie, CHADS 2 score 0-1), the performance of the ABC scores in those patients cannot be assessed. Second, by excluding 1 year of events, our power was diminished in the landmark analyses performed starting at 12 months. Third, these results do not address whether analytical variability in assay performance in the general population may have any meaningful impact on the estimation of risk. Finally, this analysis does not address the cost-effectiveness of using the ABC scores over traditional clinical risk scores to estimate risk of S/SEE and major bleeding; this is an important question for the field.
Conclusions
The ABC-stroke and ABC-bleeding risk scores reestimated in this anticoagulated clinical trial cohort were well calibrated and had significantly better discriminatory performance than the CHA 2 DS 2 -VASc and HAS-BLED clinical risk scores for the prediction of S/ SEE and major bleeding, respectively. Regardless of the CHA 2 DS 2 -VASc and HAS-BLED risk scores, the ABC-stroke and ABC-bleeding risk scores accurately stratified risk of these clinical outcomes. Application of these scores may help to identify patients who are most likely to derive benefit from treatment with nonvitamin K antagonist oral anticoagulants compared with warfarin. Incorporating these biomarker-based risk scores into clinical practice may significantly improve the risk-benefit assessment of patients with AF considering anticoagulation. 
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